This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.


Equipping Potent Cells with Validated Tumor Targeting
Chimeric antigen receptor (CAR) technology is a well-established approach to augment immune cells to fight cancer. CARs are receptors engineered to recognize specific tumor markers and can be genetically introduced to immune cells, such as NK cells or T cells. This equips these cells to recognize and engage tumor cells that possess the particular relevant marker. CAR based therapies have previously demonstrated potential benefits in the treatment of hematological malignancies.
Enhancing Potent Cell Lines with CAR-Directed Targeting
Scalable CAR Technology

Scalable CAR Technology

Combining CAR with its off-the-shelf oNK cell line, Acepodia has designed a platform capable of delivering on the efficacy of CAR-based cell therapy while being cost-effective and readily available.
Preclinical Application: Optimized CAR Candidates

Preclinical Application: Optimized CAR Candidates

Acepodia is utilizing this approach to develop ACE1755, a CD19-targeting CAR-oNK for the treatment of hematological malignancies.

Potent, Off-The-Shelf Cell Lines as the Chassis for our CAR Technology

Acepodia is applying CAR technology to both of its proprietary off-the-shelf NK (oNK) cells and gamma delta (γδ) T cells which are allogeneic, and specially selected for enhanced tumor engagement. By equipping oNK cells and gamma delta T cells with CAR, we are able to capitalize on our potent cell line’s tumor-killing potential by engineering antigen-binding receptors into these cells to drive tumor targeting by drug candidates that can be developed at a cost-effective and scalable rate.




Phase I
Phase II
ACE1755 (Safety+)
CD19 Targeting, CAR-oNK Cell Therapy
Preclinical ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.